- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00442377
Study to Investigate the Induction of an Protective Immune Response to Malaria
Exposure of Human Volunteers to Live Malaria Sporozoites Under Chloroquine Prophylaxis
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Efforts to develop vaccines against malaria still represent a substantial focus of current research activities. Factors that have hampered the development of a subunit vaccine include the complexity of the malaria life cycle, the wide variety of immune response induced by the malaria parasite, and an incomplete knowledge of protective immunity. This study is therefore aimed at inducing protective immunity against malaria in 15 healthy volunteers. Volunteers will be exposed to the bites of infectious mosquitoes 3 times with live P. falciparum sporozoites under chloroquine prophylaxis. Challenge with infected mosquitoes will be given after stopping chloroquine prophylaxis.
Five volunteers will form a control group; they will be exposed to non-infectious mosquitoes under chloroquine prophylaxis.
Endpoints include the time and height of parasitemia after challenge, the development of fever and immunological parameters.
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
-
Nijmegen, Нидерланды, 6500 HB
- Radboud University Nijmegen Medical Centre
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Age > 18 and < 45 years healthy volunteers (males or females).
- General good health based on history and clinical examination.
- All volunteers have to sign the informed consent form.
- Negative pregnancy test.
- Use of adequate contraception for females
- Reachable by phone during the whole study period.
- Volunteer agrees to inform the general practitioner and agrees to sign a request for medical information concerning contra-indications for participation in the trial
Exclusion Criteria:
- History of malaria or residence in malaria endemic areas within the past six months.
- Positive serology for P. falciparum
- Previously participated in any malaria vaccine study
- Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers.
- Cardiovascular risk >10% according to European guidelines, taking into account sex, age, cholesterol, weight, smoking habits, blood pressure, diabetes
- Any laboratory abnormalities on screened blood samples beyond the normal range, as defined at UMC St Radboud. Positive HIV, HBV or HCV tests.
- Volunteers should not be enrolled in any other clinical trial during the whole trial period.
- Volunteers should not receive chronic medication, especially immunosuppressive agents (steroids, immunomodulating or immunosuppressive drugs) during the three months preceding the screening visit or during the study period.
- Pregnant or lactating women.
- Volunteers unable to give written informed consent.
- Volunteers unable to be closely followed for social, geographic or psychological reasons.
- Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study.
- Known hypersensitivity for anti-malaria drugs
- Volunteers are not allowed to travel to malaria endemic countries during the study period.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Профилактика
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
---|
A significant difference in time of thick smear positivity between exposed and control groups
|
A significant difference in parasitemia as measured by 18S Pf NASBA between exposed and control group
|
A significant difference in kinetics of parasitemia between exposed and control groups as measured by 18S Pf NASBA.
|
A difference in occurrence or height of fever between exposed and control groups.
|
Вторичные показатели результатов
Мера результата |
---|
Significant differences in immune response between exposed and control volunteers (including NK-cell reactivity, TLR reactivity and regulatory T-cell reactivity)
|
Significant differences in the outcome of in vitro functional malaria assays between exposed and control volunteers
|
Significant differences in cellular reactivity against Pf antigens
|
Significant differences in parasite VAR gene expression during infection
|
The identification of immune mechanisms that correlate with protection
|
6. The identification of potential vaccine candidates that correlate with protection
|
Соавторы и исследователи
Следователи
- Главный следователь: Robert Sauerwein, Prof, Radboud University Medical Center
Публикации и полезные ссылки
Общие публикации
- Coffeng LE, Hermsen CC, Sauerwein RW, de Vlas SJ. The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection. PLoS Comput Biol. 2017 Jan 12;13(1):e1005255. doi: 10.1371/journal.pcbi.1005255. eCollection 2017 Jan.
- Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Renia L, van der Ven A, Hermsen CC, Sauerwein R. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009 Jul 30;361(5):468-77. doi: 10.1056/NEJMoa0805832.
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- EHMI-8
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Falciparum малярия
-
University of OxfordNanyang Technological University; Texas Biomedical Research InstituteЗавершенныйP. Falciparum Малярия | P. Falciparum Малярийная смешанная инфекцияТаиланд
-
University of OxfordПрекращеноP. Falciparum МалярияТаиланд
-
National Institute of Allergy and Infectious Diseases...ЗавершенныйОстрая малярия FalciparumМали
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces Research...ЗавершенныйНеосложненная малярия FalciparumБангладеш
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health, MyanmarНеизвестныйНеосложненная малярия FalciparumМьянма
-
Syamsudin Abdillah,Ph.D, Pharm DApt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati...ЗавершенныйНеосложненный Plasmodium falciparumИндонезия
-
Universidad Nacional de ColombiaSanofi Pasteur, a Sanofi CompanyЗавершенный
-
National Institute for Medical Research, TanzaniaWorld Health Organization; Muhimbili University of Health and Allied SciencesЗавершенныйНеосложненная малярия FalciparumТанзания
-
University of OxfordЗавершенныйТяжелая малярия FalciparumБангладеш
-
Heidelberg UniversityЗавершенныйНеосложненная малярия FalciparumБуркина-Фасо